Verastem Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
101,398.00
92,675.00
110,258.00
80,897.00
86,672.00
250,394
Total Accounts Receivable
123.00
2,348.00
154.00
204.00
-
306
Other Current Assets
434.00
293.00
431.00
194.00
1,115.00
2,232
Total Current Assets
101,955.00
95,316.00
110,843.00
81,295.00
87,787.00
253,259
Net Property, Plant & Equipment
631.00
2,825.00
2,048.00
1,417.00
861.00
1,369
Total Investments and Advances
22,344.00
203.00
203.00
162.00
162.00
-
Other Assets
331.00
305.00
-
755.00
981.00
1,031
Total Assets
125,261.00
98,649.00
113,094.00
83,629.00
89,791.00
277,236
Accounts Payable
2,760.00
-
3,942.00
-
9,186.00
Other Current Liabilities
5,044.00
9,204.00
6,167.00
10,991.00
7,942.00
Total Current Liabilities
7,804.00
9,204.00
10,109.00
10,991.00
17,128.00
Long-Term Debt
-
-
-
-
14,828.00
Other Liabilities
11.00
679.00
516.00
341.00
151.00
Total Liabilities
7,815.00
9,883.00
10,625.00
11,332.00
32,107.00
Common Equity (Total)
117,446.00
88,766.00
102,469.00
72,297.00
57,684.00
Total Shareholders' Equity
117,446.00
88,766.00
102,469.00
72,297.00
57,684.00
Total Equity
117,446.00
88,766.00
102,469.00
72,297.00
57,684.00
Liabilities & Shareholders' Equity
125,261.00
98,649.00
113,094.00
83,629.00
89,791.00

About Verastem

View Profile
Address
117 Kendrick Street
Needham Massachusetts 02494
United States
Employees -
Website http://www.verastem.com
Updated 07/08/2019
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs to treat cancer by the targeted killing of cancer stem cells. Its product candidates include duvelisib, which targets the Phosphoinositide 3-kinase signaling pathway; and defactinib, a targeted inhibitor of the Focal Adhesion Kinase signaling pathway. It evaluates these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer.